NEWS RELEASE

Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany

2026-11-19

Project modernizes insulin manufacturing and strengthens supply resilience

DALLAS--(BUSINESS WIRE)-- **Jacobs** (NYSE: J) has been selected by **Sanofi** as the Engineering, Procurement and Construction Management (EPCM) partner for a new insulin manufacturing facility in Frankfurt, Germany.

Located alongside Sanofi's established insulin manufacturing campus, the facility will support the production of multiple insulin products and strengthen supply reliability.

Jacobs will provide integrated EPCM services spanning design, procurement, construction management and commissioning. Building on its involvement during early project development, Jacobs will leverage existing site infrastructure and advanced manufacturing technologies to deliver a state-of-the-art facility.

Jacobs Executive Vice President Sean Sommer said: "Our life sciences legacy began in 1943, when our founder, Dr. Joe Jacobs, was part of the team that enabled the first commercial-scale production of penicillin. More than 80 years later, we continue to deliver the advanced manufacturing facilities behind some of the world's most important therapies."

The project will incorporate advanced manufacturing systems that support efficient and reliable operations. Jacobs will deploy an integrated team spanning engineering, procurement, project controls, construction management, commissioning, quality and safety to deliver the project from design through startup.

This award further strengthens Jacobs' position as a leading solutions provider to global pharmaceutical and

biotechnology manufacturers. Earlier this year, Engineering News-Record (ENR) ranked Jacobs the **No. 1 Pharmaceuticals Design Firm**, reflecting its leadership delivering advanced pharmaceutical manufacturing and biomanufacturing facilities. For example, Jacobs is providing EPCM services for **FUJIFILM Biotechnologies' $3.2 billion Holly Springs campus**, one of North America's largest biomanufacturing facilities, underscoring Jacobs' role in delivering complex life sciences investments at scale.

In Germany, Jacobs continues to deliver some of the country's most critical infrastructure and advanced manufacturing investments. Recent work includes **SuedLink**, one of the world's largest underground high-voltage power cable projects, a framework with **TransnetBW** supporting Germany's grid expansion and energy transition, and **thyssenkrupp** Steel's major industrial decarbonization program. With more than 300 employees across three offices in Germany, Jacobs provides integrated solutions spanning life sciences, energy, infrastructure and advanced manufacturing, helping drive innovation, resilience and long-term economic growth.

At Jacobs, we're challenging today to reinvent tomorrow – delivering outcomes and solutions for the world’s most complex challenges. With approximately $12 billion in annual revenue and a team of approximately 47,000, we provide end-to-end services in advanced manufacturing, cities & places, energy, environmental, life sciences, transportation and water. From advisory and consulting, feasibility, planning, design, program and lifecycle management, we’re creating a more connected and sustainable world. See how at **jacobs.com** and connect with us on **LinkedIn**, **Instagram**, **X** and **Facebook**.

Certain statements contained in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not directly relate to any historical or current fact. When used herein, words such as "expects," "anticipates," "believes," "seeks," "estimates," "plans," "intends," "future," "will," "would," "could," "can," "may," and similar words are intended to identify forward-looking statements. We base these forward-looking statements on management's current estimates and expectations, as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements including, but not limited to, uncertainties as to, the timing of the award of projects and funding and potential changes to the amounts provided for under the Infrastructure Investment and Jobs Act and other legislation and executive orders related to governmental spending, including any directive to federal agencies to reduce federal spending or the size of the federal workforce, and changes in U.S. or foreign tax laws, including the tax legislation enacted in the U.S. in July 2025, statutes, rules, regulations or ordinances, including the impact of, and changes to tariffs and retaliatory tariffs or trade policies, that may adversely impact our future financial positions or results of operations, as well as general economic conditions, including inflation and the actions taken by monetary authorities in response to inflation, changes in interest rates and foreign currency exchange rates, changes in capital markets, the possibility of a

recession or economic downturn, and increased uncertainty and risks, including policy risks and potential civil unrest, relating to the outcome of elections across our key markets and elevated geopolitical tension and conflicts, among others. For a description of these and additional factors that may occur that could cause actual results to differ from our forward-looking statements, see our filings with the U.S. Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.

View source version on businesswire.com: **https://www.businesswire.com/news/home/20261119968923/en/**

For press/media inquiries:
media@jacobs.com

Source: Jacobs